Tone mix
Week by week 52 weeks
Share of Vaxcyte, Inc. Common Stock's 137 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 4, 2025 · tone -98Vaxcyte (PCVX) Q2 Loss Widens 11% | The Motley Fool-140
- Week of May 4, 2026 · tone -100Vaxcyte (NASDAQ:PCVX) Releases Earnings Results, Misses Estimates By $0.56 EPS-136
- Week of Sep 28, 2026 · tone +100Vaxcyte's (PCVX) "Buy" Rating Reiterated at Needham & Company LLC+85
- Week of Aug 10, 2026 · tone +99Vaxcyte, Inc. (NASDAQ:PCVX) Receives $86.00 Consensus Target Price from Brokerages+70
- Week of Sep 15, 2025 · tone -33TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling-69
- Week of Jun 1, 2026 · tone +93Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials+62
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Vaxcyte, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 1 | 0 |
| Last 30 sessions | 23 | +61 |
| Last 90 sessions | 54 | +35 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletInvestment Analysts' Weekly Ratings Updates for Vaxcyte (PCVX)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Investment Analysts' Weekly Ratings Updates for Vaxcyte (PCVX) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletShow Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletVaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor Fitzgerald | www.dailypolitical.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 8, 2026
2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.cidrap.umn.edu · 1 outletVaxcyte's 31-strain pneumococcal conjugate vaccine passes phase 3 testPositive
- www.dailypolitical.com · 1 outletVaxcyte (NASDAQ:PCVX) Sees Large Volume Increase on Analyst UpgradePositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Vaxcyte's 31-strain pneumococcal conjugate vaccine passes phase 3 test | www.cidrap.umn.edu | 1 | Positive |
| Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase on Analyst Upgrade | www.dailypolitical.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 7, 2026
2 headlines, average tone -50: 0 positive, 1 neutral and 1 negative. Showing all 2.
- www.investors.com · 1 outletBiotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersNegative
- www.manilatimes.net · 1 outletVaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers | www.investors.com | 1 | Negative |
| Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Vaxcyte, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.